Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
Harvard University · Massachusetts General Hospital · +36 more institutions
Abstract
-altered tumors and strong preclinical activity against acquired resistance mutations associated with ATP-competitive FGFR inhibitors.
rearrangement-positive intrahepatic cholangiocarcinoma and disease progression after one or more previous lines of systemic therapy (excluding FGFR inhibitors). The patients received oral futibatinib at a dose of 20 mg once daily in a continuous regimen. The primary end point was objective response (partial or complete response), as assessed by independent central review. Secondary end points included the response duration, progression-free and overall survival, safety, and patient-reported outcomes.
Citation impact
- FWCI
- 75.33
- Percentile
- 100%
- References
- 40
Authors
30- LGLipika GoyalCorresponding
Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, University College London
- FMFunda Meric‐Bernstam
The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, University College London
- AHAntoine Hollebecque
Institut Gustave Roussy, Dana-Farber Cancer Institute, University College London
- JWJuan W. Valle
University of Manchester, Dana-Farber Cancer Institute, The Christie NHS Foundation Trust, University College London
- CMChigusa Morizane
Dana-Farber Cancer Institute, Tokyo National Hospital, University College London
Topics & keywords
- Medicine
- Internal medicine
- Intrahepatic Cholangiocarcinoma
- Gastroenterology
- Clinical endpoint
- Hyperphosphatemia
- Adverse effect
- Progressive disease
- Good health and well-being